| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 16, 2026 | 11d | — | — | 0 | 0 |
| Nov 20, 2026 | 46d | — | — | 0 | 0 |
| Jan 15, 2027 | 102d | — | — | 0 | 0 |
| Feb 19, 2027 | 137d | — | — | 0 | 0 |
| May 21, 2027 | 228d | — | — | 0 | 0 |
| Jan 21, 2028 | 473d | — | — | 0 | 0 |
| Jan 19, 2029 | 837d | — | — | 0 | 0 |
cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un